The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 1,250 companies had the same profile as MAYAKU PHARMACEUTICAL DEVELOPMENT has now. Each dot stands for 4 companies, two years later.
94.4%
were still trading
2.7%
stopped another way
2.6%
went bankrupt
Micro
5 to 10 years old
solvency under 10%
a profit under 5% of the balance sheet
Another 0.3% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,250 companies, not a prediction for MAYAKU PHARMACEUTICAL DEVELOPMENT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit check for an amount and term of your choice
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0755350975
Registered office moved from Ghent to Zwijnaarde
The registered office moved from Hamerstraat 41 9000 Gent to Technologiepark - Zwijnaarde 82 9052 Zwijnaarde · Gazette deed
First establishment
At the time the registered office was still in Gent, Hamerstraat 41.
Incorporation
Founding capital of €2,000, 100 shares · Founded by Name after signing inVisible after signing in · Name hiddenVisible after signing in appointed as director · published on 01-10-2020 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as MAYAKU PHARMACEUTICAL DEVELOPMENT: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €150,000 and €245,000, founded between 2019 and 2022.
MAYAKU PHARMACEUTICAL DEVELOPMENT files the micro format. That format states no turnover. The gross margin rose from €43,079 in 2021 to €104,752 in 2025.
According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
What is the legal form of MAYAKU PHARMACEUTICAL DEVELOPMENT?
MAYAKU PHARMACEUTICAL DEVELOPMENT is a private limited company (BV).
When was MAYAKU PHARMACEUTICAL DEVELOPMENT founded?
MAYAKU PHARMACEUTICAL DEVELOPMENT was founded on 29-09-2020.
Is MAYAKU PHARMACEUTICAL DEVELOPMENT still active?
Yes, MAYAKU PHARMACEUTICAL DEVELOPMENT is an active enterprise in the KBO register.
How many employees does MAYAKU PHARMACEUTICAL DEVELOPMENT have?
MAYAKU PHARMACEUTICAL DEVELOPMENT had an average of 1.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of MAYAKU PHARMACEUTICAL DEVELOPMENT?
The turnover in financial year 2025 is about €260,000. This figure is estimated from the gross margin of €104,752 and 2,458 comparable companies of the same size. It probably lies between €170,000 and €410,000. It is a rough estimate.
Is MAYAKU PHARMACEUTICAL DEVELOPMENT profitable?
In financial year 2025, MAYAKU PHARMACEUTICAL DEVELOPMENT made a profit of €1,553.
Where can I find the annual accounts of MAYAKU PHARMACEUTICAL DEVELOPMENT?
MAYAKU PHARMACEUTICAL DEVELOPMENT filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MAYAKU PHARMACEUTICAL DEVELOPMENT due?
MAYAKU PHARMACEUTICAL DEVELOPMENT must file the annual accounts for financial year 2026 by 31-07-2027.Timeline